Abstract
Human neuroblastoma cells contain a 260 kDa surface-associated antigen (NB-p260) that is recognised by natural cytotoxic IgM antibodies. In this study we demonstrate that NB-p260 is expressed in vivo in a neuroblastoma tumour specimen but not in normal human tissues of neuronal origin. Since MYCN amplification is a clinical marker of neuroblastoma disease progression, we analysed the expression of NB-p260 in human neuroblastoma cell lines with different MYCN amplification status. However, both amplified and non- amplified neuroblastoma cell lines exhibited comparable NB-p260 expression. Treatment of neuroblastoma cells with the differentiation-inducing agent retinoic acid (RA) also had no effect on the expression of NB-p260. Collectively, the data suggest that expression of NB-p260 on human neuroblastoma cells is independent of malignancy and differentiation status of neuroblastoma.
| Original language | English |
|---|---|
| Pages (from-to) | 1937-1941 |
| Number of pages | 5 |
| Journal | European Journal of Cancer |
| Volume | 33 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Oct 1997 |
| Externally published | Yes |
Keywords
- MYCN
- Natural antibodies
- Neuroblastoma
- Retinoid acid
- Tumour antigen
Fingerprint
Dive into the research topics of 'Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: Correlation to MYCN amplification and effects of retinoic acid'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver